GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus

Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody against the GP...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines Vol. 8; no. 1; pp. 73 - 17
Main Authors: Scher, Gabrielle, Bente, Dennis A., Mears, Megan C., Cajimat, Maria N. B., Schnell, Matthias J.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 20.05.2023
Nature Publishing Group
Nature Portfolio
Subjects:
631/250/590/1883
631/326/596/2561
Biomedical and Life Sciences
Biomedicine
Glycoproteins
Hemorrhage
Infectious Diseases
Medical Microbiology
Monoclonal antibodies
Parasitic diseases
Public Health
Rodents
Vaccine
Vaccines
Viral infections
Virology
ISSN:2059-0105, 2059-0105
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic disease in humans. There is a great need for effective vaccines and therapeutics against CCHFV for humans, as none are currently internationally approved. Recently, a monoclonal antibody against the GP38 glycoprotein protected mice against lethal CCHFV challenge. To show that GP38 is required and sufficient for protection against CCHFV, we used three inactivated rhabdoviral-based CCHFV-M vaccines, with or without GP38 in the presence or absence of the other CCHFV glycoproteins. All three vaccines elicited strong antibody responses against the respective CCHFV glycoproteins. However, only vaccines containing GP38 showed protection against CCHFV challenge in mice; vaccines without GP38 were not protective. The results of this study establish the need for GP38 in vaccines targeting CCHFV-M and demonstrate the efficacy of a CCHFV vaccine candidate based on an established vector platform.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-023-00663-5